RT Journal Article SR Electronic T1 Newborn Differential DNA Methylation and Subcortical Brain Volumes as Early Signs of Severe Neurodevelopmental Delay in a South African Birth Cohort Study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.13.20035501 DO 10.1101/2020.03.13.20035501 A1 Anke Hüls A1 Catherine J Wedderburn A1 Nynke A Groenewold A1 Nicole Gladish A1 Meaghan Jones A1 Nastassja Koen A1 Julia L MacIsaac A1 David TS Lin A1 Katia E Ramadori A1 Michael P Epstein A1 Kirsten A. Donald A1 Michael S Kobor A1 Heather J Zar A1 Dan J Stein YR 2020 UL http://medrxiv.org/content/early/2020/04/17/2020.03.13.20035501.abstract AB Objective The first two years of life are a critical period of rapid brain development. Since early neurodevelopment is influenced by prenatal risk factors and genetics, neonatal biomarkers can potentially provide the opportunity to detect early signs of neurodevelopmental delay. We analyzed associations between DNA methylation (DNAm) levels from cord blood, neonatal magnetic resonance imaging (MRI) neuroimaging data, and neurodevelopment at two years of age.Methods Neurodevelopment was assessed in 161 children from the South African Drakenstein Child Health Study at two years of age using the Bayley Scales of Infant and Toddler Development III. We performed an epigenome-wide association study of neurodevelopmental delay using DNAm levels from cord blood. A mediation analysis was conducted in 51 children to analyze if associations between differential DNAm and neurodevelopmental delay were mediated by altered neonatal brain volumes.Results We found epigenome-wide significant associations between differential DNAm at the SPTBN4 locus (cg26971411, p-value=3.10×10−08), an intergenic region on chromosome 11 (cg00490349, p-value=2.41×10−08) and a differentially methylated region on chromosome 1 (FDR p-value for the region=9.06×10−05) and severe neurodevelopmental delay. While these associations were not mediated by neonatal brain volume, neonatal caudate volumes were independently associated with neurodevelopmental delay, particularly in language (p=0.0443) and motor (p=0.0082) domains.Conclusion Differential DNAm levels from cord blood and increased neonatal caudate volumes were independently associated with severe neurodevelopmental delay at two years of age. These findings suggest that neurobiological signals for severe developmental delay may be detectable in very early life with implications for identification and intervention design.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Drakenstein Child Health Study was funded by the Bill & Melinda Gates Foundation (OPP 1017641), Discovery Foundation, Medical Research Council South Africa, National Research Foundation South Africa, CIDRI Clinical Fellowship and Wellcome Trust (204755/2/16/z). Additional support for the DNA methylation work was by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NICHD) under Award Number R21HD085849, and the Fogarty International Center (FIC). AH was supported by a research fellowship from the Deutsche Forschungsgemeinschaft (DFG; HU 2731/1-1) and by the HERCULES Center (NIEHS P30ES019776). MPE was supported by NIH grant R01 GM117946. NAG was supported by a Claude Leon Fellowship. DJS, HJZ and KAD are supported by the South African Medical Research Council (SAMRC). CJW is supported by the Wellcome Trust through a Research Training Fellowship [203525/Z/16/Z]. Support for the neuroimaging was also received by KAD from an ABMRF young investigator grant, the Brain & Behavior Research Foundation Independent Investigator grant (24467) and NIH-R21AA023887 and the Harry Crossley Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request from the Steering Committee (Prof. Heather Zar, heather.zar@uct.ac.za)